SYMATESE enters into exclusive Licensing Agreement with EVOLUS

SYMATESE broadens its commercial territories in Europe and United Kingdom for ESTYME® FILLERS, based on its Next-Generation generation HA technology EVOLUS neurotoxin, NUCEIVA® will be marketed in France by SYMATESE subsidiary.

SYMATESE announced today that it has entered into a second agreement with EVOLUS.  The second agreement expands EVOLUS’ distribution rights to now include the exclusive distribution in Europe and United Kingdom of SYMATESE’ four unique dermal fillers in late-stage development with anticipated regulatory clearances in the second half of 2024 and commercialization under the brand name ESTYME® FILLERS in 2025. The first agreement was granting exclusive distribution rights to the same product line in the U.S., where it will be commercialized under the brand name EVOLYSSETM, with now a total market reach for EVOLUS of 2.38 billion €.

Jean-Paul Gérardin, CEO of SYMATESE stated: “We are pleased to reinforce our partnership with EVOLUS, based on a unique portfolio creation in Europe combining ESTYME® FILLERS with its neurotoxin, NUCEIVA®. SYMATESE will market these two product ranges in France. Regulatory approval has already been received for the first nasolabial fold product ESTYME® LIFT.

Through this novel agreement, we confirm that our science of tissue regeneration and reconstruction combined with our administration systems gives SYMATESE a unique position in the facial rejuvenation market and other therapeutic indications. Its next generation HA technology and its clinical program will be introduced at IMCAS, 1- 3 February 2024 during lectures.”


About Evolus, Inc.

Evolus (Nasdaq: EOLS) is a performance beauty company evolving the aesthetic neurotoxin market for the next generation of beauty consumers through its unique, customer-centric business model and innovative digital platform. Our mission is to become a global, multi-product aesthetics company based on our flagship product, Jeuveau® (prabotulinumtoxinA-xvfs), the first and only neurotoxin dedicated exclusively to aesthetics and manufactured in a state-of-the-art facility using Hi-Pure™ technology. Evolus is expanding its product portfolio having entered into a definitive agreement to be the exclusive U.S. distributor of Evolysse™, and the exclusive distributor in Europe of ESTYME®, a line of unique dermal fillers currently in late-stage development. Visit us at, and follow us on LinkedInXInstagram or Facebook.

 About Symatese

Founded 25 years ago by Eric Perouse and Jean-Paul Gérardin, SYMATESE is a privately held French company specializing in Class I to III medical devices.  The company maintains an international presence through six subsidiaries and four manufacturing facilities employing a team of 400 persons and 40 researchers.  At the heart of SYMATESE’s research is the science of tissue regeneration and reconstruction for the benefit of doctors and patients. Every year, more than 25 million patients worldwide are treated thanks to its innovative hyaluronic acid, collagen, thermoplastic and silicone technologies.  SYMATESE is able to address the most delicate and complex health issues based on its expertise in 15 therapeutic specialties, aesthetic medicine and its associated administration systems, while also relying on its own product and technology brands. Research & development partnerships with major global companies and from now on with Evolus, demonstrate this strong scientific and technological excellence.  For more information, visit us at, and follow us on Linkedin.